National Agri-Marketing Association
NAMA Website
Upcoming Events
Agri-Marketing Conf
Best of NAMA 2017
Member Directory

Source: Boehringer Ingelheim news release

To view the complete report, click here.

The research-driven pharmaceutical company Boehringer Ingelheim overcame major challenges in the first half of 2014. These included the settlement of lawsuits over PRADAXA® in the USA and the sale of certain key assets of Bedford Laboratories, which was concluded in July.

Bedford Laboratories is a provider of generic injectable medicines in the USA under the corporate umbrella of the Boehringer Ingelheim subsidiary Ben Venue Laboratories Inc. An agreement on the sale of the production facilities and the premises of Ben Venue in Bedford, Ohio, has since been reached.

In addition, the US Food and Drug Administration (FDA) at the beginning of June lifted the Warning Letter for its Ingelheim manufacturing facility.

At the same time, the pressure resulting from the rapidly changing global market and economic conditions has increased sharply. Particularly in the USA, Boehringer Ingelheim, triggered by reforms to the healthcare system, was forced to accept significant price reductions.

Currency-adjusted net sales at around €6.5 billion in the first half of 2014 were thus three percent below the level of the same period last year (in euro terms: -7.9 percent).

In the business area Animal Health, Boehringer Ingelheim reported currency-adjusted growth of six percent to €536 million.

Search News & Articles

Proudly associated with:
American Business Media Canadian Agri-Marketing Association National Agri-Marketing Association
Agricultural Relations Council National Association of Farm Broadcasters American Agricultural Editors' Association Livestock Publications Council
All content © 2017, Henderson Communications LLC. | User Agreement